The prognostic role of Claudin-1 expression in prostatic adenocarcinoma: Immunohistochemical study

The incidence of prostate cancer has increased greatly with the popularization of the prostate-specific antigen test and increasing growth of elderly population. Different expression levels of Claudin-1 have been reported in various tumors including prostate cancer. The aim of this study was to clarify the immunohistochemical expression of Claudin-1 and its associations with clinicopathological data to assess its prognostic role in prostatic adenocarcinoma. The study material consisted of 75 randomly selected prostatic adenocarcinoma and 45 nodular prostatic hyperplasia samples. All cases obtained by transurethral retrograde prostatectomy and were collected from the Pathology Department, Faculty of Medicine, Menoufia University, derived from 2010 to 2015. Overall survival time was available for 51 out of 75 patients. There was a highly statistical significant difference between high Claudin-1 expression and membranocyroplasmic pattern of expression and low PSA level (P = 0.005 and 0.02 respectively), low Gleason score (≤ 6) (P < 0.000 and 0.002 respectively) and absence of metastasis (P = 0.013 “significant” and < 0.000 respectively). Claudin-1 pattern of expression proved to be the most independent prognostic factor on overall survival of prostatic adenocarcinoma patients (P = 0.002) by Multivariate survival analysis. All nodular prostatic hyperplasia cases and normal prostate showed membranous pattern. Claudin-1 is proved to be the most independent prognostic factor on overall survival patients. Also it might be a promising molecular marker for prognosis and therapy in prostatic adenocarcinoma. Citation: Holah NS (2016). The prognostic role of Claudin-1 expression in prostatic adenocarcinoma: Immunohistochemical study. Molecular Biology Research and Innovations 1: 10-18. Received February 18, 2016; Revised March 12, 2016; Accepted March 18, 2016; Published March 25, 2016. Copyright: © 2016 Holah NS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. MBRI is a journal publication of BRSF. Competing Interests: The authors have declared that no competing interests exist. * E-mail: shawkyholah@yahoo.com